These results were consistent with previously published data on anti–PD-1 monotherapies combined with various neoadjuvant regimens.25,26,27 However, 20% of patients in the CRT plus ipilimumab and nivolumab group required discontinuation due to ICI-induced hepatitis, myositis, or diarrhea. The gene discussed is PDCD1; the disease is myositis disease.